MAP
BEAM icon

Moody Aldrich Partners’s Beam Therapeutics BEAM Stock Holding History

Moody Aldrich Partners’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-25,995
Closed -$1.49M – 147
2022
Q1 		$1.49M Buy
25,995
+1,901
+8% +$125K 0.21% 99
2021
Q4 		$1.92M Sell
24,094
-4,537
-16% -$388K 0.27% 95
2021
Q3 		$2.49M Buy
28,631
+4,015
+16% +$403K 0.32% 89
2021
Q2 		$3.17M Buy
+24,616
New +$1.96M 0.45% 81

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Moody Aldrich Partners's BEAM Position: Q2 2022 in Review

Moody Aldrich Partners sold out of Beam Therapeutics (BEAM) in Q2 2022, closing a stake of 25,995 shares — an estimated $1.49M sold.

Moody Aldrich Partners first reported a position in BEAM in Q2 2021 and held it in 4 quarters. The position peaked at $3.17M in Q2 2021. 205 funds tracked by Wall St. Rank hold BEAM as of Q2 2022.

  • Moody Aldrich Partners reported no remaining Beam Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Moody Aldrich Partners sold 25,995 Beam Therapeutics shares in Q2 2022, an estimated $1.49M.
  • Moody Aldrich Partners first reported a position in Beam Therapeutics in Q2 2021 and held it in 4 quarters.
  • Moody Aldrich Partners's Beam Therapeutics position peaked at $3.17M in Q2 2021.
  • 205 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2022.

Based on Moody Aldrich Partners's 13F filing for Q2 2022, filed 18 Jul 2022.